ENDRA Life Sciences Inc. is a biotech company developing a medical device for liver fat measurement to aid in metabolic disease detection and management, currently in the development stage with no revenue but incurring significant losses.

# Company Summary: ENDRA Life Sciences Inc.

**Overview:**  
ENDRA Life Sciences Inc. is a biotechnology company focused on developing medical devices for liver fat measurement and related applications in metabolic disease detection and management.

---

## Core Business Activities:  
- Designing and developing a **medical device** for **accurate liver fat measurement**.  
- The device is intended for use in **metabolic disease detection**, **management**, and **GLP-1 drug eligibility**—particularly in circumstances where other technologies are impractical or unavailable.

---

## Financial and Operational Details:  
- **Number of Employees:** Not explicitly specified in the document.  
- **Number of Customers:** Not provided.  
- **Revenue:** The company has **not generated any product revenue** to date.  
- **Net Income (Loss):**  
  - For the fiscal year ending December 31, 2024:  
    - **Net Loss:** **$11,507,947**  
  - For the previous year ending December 31, 2023:  
    - **Net Loss:** **$10,060,250**  

## Financial Position (as of December 31, 2024):  
- **Cash and Cash Equivalents:** Approximately **$3,229,480**  
- **Total Assets:** About **$4,452,362**  
- **Total Liabilities:** Approximately **$1,891,996**  
- **Stockholders’ Equity:** Around **$2,560,366**

---

## Key Notes:
- The company is still in the development stage with significant expenses in research & development and sales & marketing.
- The company has ongoing funding activities, including public offerings and warrants, but has not yet established commercial revenue streams.
- The company operates as a **single operating segment** focused on biomedical innovation (biotech).
- The company is presently a **smaller reporting company** and has a limited historical track record of revenue or profit.

---

## Summary:  
ENDRA Life Sciences Inc. is a biotech firm working on a novel liver fat measurement device targeting metabolic diseases. It is pre-revenue, incurring substantial operating losses, and actively raising capital through equity offerings. It employs an undisclosed number of staff, with no current customer or revenue data available, and its financial health is heavily reliant on continued fundraising efforts.

ENDRA Life Sciences Inc. develops innovative ultrasound technology for safe and accessible diagnosis and treatment of medical conditions, with a focus on liver diseases.

# Summary of ENDRA Life Sciences Inc.

## Company Overview
ENDRA Life Sciences Inc. is a Delaware corporation incorporated in 2007, focused on developing a next-generation enhanced ultrasound technology platform known as Thermo Acoustic Enhanced Ultrasound (TAEUS®). The aim of this technology is to broaden patient access to the safe diagnosis and treatment of significant medical conditions, particularly in circumstances where traditional imaging modalities like CT scans and MRIs are not practical or available.

## Technology
- **Thermoacoustic Technology**: ENDRA's TAEUS technology utilizes low-power radio frequency (RF) pulses to stimulate tissues, leading to the generation of ultrasound signals that enable deep-tissue imaging.
- **Applications**: The first application of TAEUS targets the quantification of fat in the liver and the staging of **nonalcoholic fatty liver disease (NAFLD)**, which can progress to severe liver conditions like Nonalcoholic Steatohepatitis (NASH) and liver cancer.
- **Market Advantages**: The TAEUS system offers a low-cost, non-invasive alternative to MRI and biopsy, which are often expensive and impractical for repeated use in monitoring liver diseases.

## Development and Commercialization
- **Regulatory Approvals**: The TAEUS Fatty Liver Imaging Probe (FLIP) received CE mark approval in March 2020. ENDRA is also pursuing FDA clearance through the "de novo" pathway, with a scheduled pre-submission meeting in Q2 2024 and expected submission in H1 2025.
- **Clinical Studies**: As of December 31, 2023, ENDRA maintains seven clinical evaluation agreements across North America, Europe, and Asia for studies comparing TAEUS to MRI.

## Market Presence
- **Global Market**: The global diagnostic ultrasound device market was valued at **$7.7 billion in 2023**, with a projected CAGR of **4.07%** from 2022 to 2030. ENDRA estimates its **addressable market** for its TAEUS applications to be approximately **700,000 ultrasound systems** currently in use globally.
  
## Financials
- **Revenue and Income**: ENDRA has **generated limited revenues** to date, with an **accumulated deficit** of **$91.9 million** as of December 31, 2023. The company has a history of operating losses and has significant ongoing expenditures related to product development and marketing efforts.
- **Number of Employees**: As of December 31, 2023, ENDRA has **21 full-time employees**, with roles distributed across research and development, sales, product assembly, and administration.

## Strategic Partnerships
- **Collaboration with GE Healthcare**: ENDRA entered a Collaborative Research Agreement with GE Healthcare in April 2016 to assist with commercialization efforts for the TAEUS fatty liver application.
- **Clinical Partnerships**: ENDRA has initiated partnerships with various universities and medical institutes for conducting clinical studies.

## Long-term Vision
ENDRA aims to leverage its unique capabilities in ultrasound technology to provide advanced imaging solutions that meet unmet medical needs, particularly in the monitoring of liver disease and other potential applications like temperature monitoring in thermoablation surgery and vascular imaging. The company is transitioning to licensing its technology to original equipment manufacturers (OEMs) for incorporation into new diagnostic systems.

ENDRA Life Sciences Inc.

10-K / April 7, 2025

10-K / March 28, 2024

10-K / April 7, 2025

Company Summary: ENDRA Life Sciences Inc.

Core Business Activities:

Financial and Operational Details:

Financial Position (as of December 31, 2024):

Key Notes:

Summary: